Former Senior Vice President of Research, Amgen
Dr. Alexander (Sasha) Kamb, Ph.D. served as Senior Vice President of Discovery Research at Amgen, Inc. until January 2017. Dr. Kamb joined Amgen to direct Oncology Research at their South San Francisco site in 2006. A year later, he took over the leadership of the Neuroscience Therapeutic Area and was promoted to Vice President, Research with the remit to build the Genome Analysis Unit, a specialized department within Amgen Research focused on cross-disease-area applications of next-generation sequencing. At the end of 2011, Dr. Kamb was promoted to Senior Vice President to head all of Amgen’s discovery research.
Prior to joining Amgen, Dr. Kamb worked in the biotechnology sector for over a decade, specializing in the genetics of cancer and development of oncology pharmaceuticals. Prior to leading the Novartis Oncology Research Group, Dr. Kamb founded Arcaris, Inc., as President, Chief Executive Officer and Chief Scientific Officer, where he directed research and business efforts focused on discovery of novel pharmaceutical targets. Arcaris was acquired by Deltagen Proteomics, Inc. Previously, Dr. Kamb was Director of Research at Myriad Genetics, Inc. and led groups that identified genes responsible for familial melanoma and breast cancer.
Dr. Kamb carried out his postdoctoral work in protein crystallography with Nobel laureate Dr. Harold Varmus, Cynthia Kenyon and Robert Stroud at the University of California, San Francisco. Dr. Kamb received his Ph.D. from the California Institute of Technology and his B.A. from Harvard College.